Drug Profile


Alternative Names: LY 110140; Prozac; Prozac Weekly; Reneuron; Sarafem

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antidepressants; Eye disorder therapies; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bulimia nervosa; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Premenstrual dysphoric disorder
  • Discontinued Dysthymic disorder; Post-traumatic stress disorders

Most Recent Events

  • 01 Mar 2015 Eli Lilly completes a phase III extension trial in Major depressive disorder in Japan (NCT01808651)
  • 01 Jul 2014 Eli Lilly completes a phase III trial in Major depressive disorder in Japan (NCT01808612)
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top